Virtual Library

Start Your Search

Samuel Rivera Rivera



Author of

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-18 - NGS-Molecular Characterization of Lung Adenocarcinomas from Hispanic Patients: Level of Evidence for Therapeutic Actionability (ID 2599)

      08:00 - 18:00  |  Author(s): Samuel Rivera Rivera

      • Abstract

      Background

      Several studies have shown that NSCLC genomic background among Hispanics differs from other populations, therefore genotyping tumors in order to assess their molecular profile is adamantly needed in the current era of targeted therapy. Panel-detected oncodriver mutations can drive therapeutic approaches, and can help classify the information in order to propose strong evidence-based interventions in treatment guidelines. In this study we sought to understand the landscape of genomic drivers in a cohort of patients with lung adenocarcinoma of Hispanic ancestry.

      Method

      Tumor samples were collected from 48 patients with lung adenocarcinoma from march 2017 until march 2019. Samples were submitted for testing to Foundation Medicine and hybrid capture NGS was performed.

      Result

      figura 1_fo.pngfigura 2_fo.pngA total of 282 samples were sent for evaluation, among which 48 (17%) with lung adenocarcinoma were tested by FoundationOne (FO) in tumor tissue. Among the patients included, 54.2% were men and 79.2% were >50 years of age. Most patients had a previous negative report for EGFR and ALK (in tumor tissue). Results for tumor mutation burden (TMB) were obtained from 48 (100%) samples. Median TMB was 4 mutations/Megabase (m/Mb). High TMB (>10 m/Mb) was identified in 9 (18.8%) samples. The most frequently detected alterations were in P53, KRAS and EGFR genes (Figure1). In terms of the level of evidence for therapeutic actionability, level-1 was 33.5 %, level-2 was 12.5%, level-3 14.6% and level-4 37.5%. (Figure 2).

      Conclusion

      Despite an initial assessment of actionable alterations (EGFR and ALK), through a NGS-approach we were able to detect a high amount of genomic alterations linked to a high-level of evidence for therapeutic actionability (33.5%), possibly due to higher sensitivity and a higher number of genes tested in the panel, increasing therapeutic options in this molecular-driven era. This research work was conducted with the support of Roche Foundation Medicine.